FDA clears AI platform for planning ahead of TAVR, other heart procedures

DASI Simulations, an Ohio-based healthcare technology company, has gained U.S. Food and Drug Administration (FDA) clearance for an artificial intelligence (AI) offering that identifies and measures cardiac structures in CT scans. 

The company’s DASI Dimensions platform was developed to help care teams plan ahead of transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The cloud-based software was developed in the research lab of the company’s founder and chief technology officer, Lakshmi Prasad Dasi, PhD, a bioengineer with Georgia Tech University. 

DASI Simulations previously gained FDA approval for PrecisionTAVI, an advanced AI model capable of predicting certain patient outcomes before patients undergo TAVR.

“Our mission—to provide an AI-powered structural heart platform that allows physicians to be more efficient and use their expertise more effectively—is moving forward with great momentum,” Teri Sirset, founder and CEO of DASI Simulations, said in a statement.

“Clinical studies conducted with the AI-powered DASI technology, coupled with cutting-edge computational modeling, have consistently demonstrated substantial improvements in patient outcomes. By reducing complications and decreasing costs, DASI Simulations is driving a transformation in the healthcare landscape,” added Vinod Thourani, MD, a cardiovascular surgeon with Piedmont Healthcare and chair of the DASI Medical Advisory Board.

Cardiology’s momentum as an AI leader continues

The DASI Dimensions approval is just the latest example of cardiology’s role as a significant leader in the development and use of healthcare AI. Cardiology ranks No. 2 among all specialties when it comes to cleared AI algorithms, trailing only radiology.

Siemens Healthineers, Nanox.AI and AISAP have all gained key FDA clearances/approvals since Aug. 1, suggesting this trend is not slowing down anytime soon. The FDA even named a cardiologist—digital health specialist Ami B. Bhatt, MD—as the first chair of its new Digital Health Advisory Committee, highlighting the prominent roles cardiologists are having in AI-related conversations on a regular basis. 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."